Free Trial

Gilead Sciences (GILD) Financials

Gilead Sciences logo
$109.09 +1.72 (+1.60%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$109.22 +0.13 (+0.12%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Gilead Sciences

Annual Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
480 5,665 4,592 6,225 123 5,386 5,455 4,628 13,501 18,108
Consolidated Net Income / (Loss)
480 5,613 4,566 6,201 89 5,364 5,460 4,644 13,488 18,106
Net Income / (Loss) Continuing Operations
479 5,612 4,566 6,201 89 5,364 5,460 4,644 13,488 18,106
Total Pre-Tax Income
690 6,859 5,814 8,278 1,669 5,160 7,799 13,529 17,097 21,659
Total Operating Income
1,662 7,605 7,330 9,918 4,071 4,287 8,200 14,124 17,633 22,193
Total Gross Profit
22,503 20,618 21,624 20,704 20,117 17,774 17,274 21,736 26,129 28,633
Total Revenue
28,754 27,116 27,281 27,305 24,689 22,449 22,127 26,107 30,390 32,639
Operating Revenue
28,754 27,116 27,281 27,305 24,689 22,449 22,127 26,107 30,390 32,151
Total Cost of Revenue
6,251 6,498 5,657 6,601 4,572 4,675 4,853 4,371 4,261 4,006
Operating Cost of Revenue
6,251 6,498 5,657 6,601 4,572 4,675 4,853 4,371 4,261 4,006
Total Operating Expenses
20,841 13,013 14,294 10,786 16,046 13,487 9,074 7,612 8,496 6,440
Selling, General & Admin Expense
6,091 6,090 5,673 5,246 5,151 4,381 4,056 3,878 3,398 3,426
Research & Development Expense
10,570 6,873 5,921 5,540 10,895 9,106 5,018 3,734 5,098 3,014
Impairment Charge
4,180 50 2,700 0.00 0.00 - - - - -
Total Other Income / (Expense), net
-971 -746 -1,516 -1,640 -2,402 873 -401 -595 -536 -534
Interest Expense
977 944 935 1,001 984 995 1,077 1,118 964 688
Other Income / (Expense), net
6.00 198 -581 -639 -1,418 1,868 676 523 428 154
Income Tax Expense
211 1,247 1,248 2,077 1,580 -204 2,339 8,885 3,609 3,553
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 -52 -26 -24 -34 -22 5.00 16 -13 -2.00
Basic Earnings per Share
$0.38 $4.54 $3.66 $4.96 $0.10 $4.24 $4.20 $3.54 $10.08 $12.37
Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.26B 1.26B 1.26B 1.27B 1.30B 1.31B 1.34B 1.46B
Diluted Earnings per Share
$0.38 $4.50 $3.64 $4.93 $0.10 $4.22 $4.17 $3.51 $9.94 $11.91
Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.26B 1.26B 1.28B 1.31B 1.32B 1.36B 1.52B
Weighted Average Basic & Diluted Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.26B 1.26B 1.30B 1.31B 1.34B 1.46B
Cash Dividends to Common per Share
$3.08 $3.00 $2.92 $2.84 $2.72 $2.52 $2.28 $2.08 $1.84 $1.29

Quarterly Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
1,315 1,783 1,253 1,614 -4,170 1,430 2,180 1,045 1,010 1,640 1,789
Consolidated Net Income / (Loss)
1,315 1,783 1,253 1,614 -4,170 1,417 2,172 1,039 985 1,633 1,786
Net Income / (Loss) Continuing Operations
1,315 1,782 1,253 1,615 -4,171 1,417 2,172 1,039 984 1,633 1,786
Total Pre-Tax Income
1,649 2,167 956 2,053 -4,486 1,653 2,318 1,588 1,300 2,031 2,432
Total Operating Income
2,237 2,452 888 2,644 -4,322 1,612 2,623 1,665 1,705 2,267 2,837
Total Gross Profit
5,127 5,988 5,971 5,410 5,134 5,024 5,486 5,157 4,951 5,993 5,647
Total Revenue
6,667 7,569 7,545 6,954 6,686 7,114 7,051 6,599 6,352 7,389 7,042
Operating Revenue
6,667 7,569 7,545 6,954 6,686 7,114 7,051 6,599 6,352 7,389 7,042
Total Cost of Revenue
1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395
Operating Cost of Revenue
1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395
Total Operating Expenses
2,890 3,536 5,083 2,766 9,456 3,411 2,863 3,492 3,247 3,726 2,810
Selling, General & Admin Expense
1,258 1,906 1,433 1,377 1,375 1,607 1,315 1,849 1,319 2,020 1,213
Research & Development Expense
1,632 1,630 1,900 1,389 5,651 1,754 1,548 1,643 1,928 1,706 1,597
Impairment Charge
0.00 - 1,750 0.00 2,430 50 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net
-588 -284 68 -592 -163 40 -304 -78 -404 -236 -405
Interest Expense
260 248 238 237 254 252 232 230 230 226 229
Other Income / (Expense), net
-328 -36 306 -355 91 292 -72 152 -174 -10 -176
Income Tax Expense
334 385 -297 438 -315 236 146 549 316 398 646
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 - 0.00 0.00 0.00 -12 -8.00 -6.00 -26 -7.00 -3.00
Basic Earnings per Share
$1.06 $1.43 $1.00 $1.29 ($3.34) $1.14 $1.75 $0.84 $0.81 $1.30 $1.43
Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.26B 1.26B
Diluted Earnings per Share
$1.04 $1.43 $1.00 $1.29 ($3.34) $1.14 $1.73 $0.83 $0.80 $1.29 $1.42
Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B
Weighted Average Basic & Diluted Shares Outstanding
1.24B 1.25B 1.25B 1.24B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B
Cash Dividends to Common per Share
$0.79 - $0.77 $0.77 $0.77 - $0.75 $0.75 $0.75 - $0.73

Annual Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
3,906 673 74 -659 -5,634 -6,309 10,437 -778 -4,622 2,824
Net Cash From Operating Activities
10,828 8,006 9,072 11,384 8,168 9,144 8,400 11,898 17,047 21,250
Net Cash From Continuing Operating Activities
10,828 8,005 9,072 11,384 8,168 9,144 8,400 11,898 17,047 21,250
Net Income / (Loss) Continuing Operations
480 5,613 4,566 6,201 89 5,364 5,460 4,644 13,488 18,106
Consolidated Net Income / (Loss)
480 5,613 4,566 6,201 89 5,364 5,460 4,644 13,488 18,106
Depreciation Expense
381 354 323 329 288 255 226 233 177 161
Amortization Expense
2,386 2,339 1,780 1,721 1,192 1,149 1,203 1,053 981 937
Non-Cash Adjustments To Reconcile Net Income
10,305 2,964 5,718 2,760 8,451 5,272 2,161 942 974 944
Changes in Operating Assets and Liabilities, net
-2,724 -3,265 -3,315 373 -1,852 -2,896 -650 5,026 1,427 1,102
Net Cash From Investing Activities
-3,449 -2,265 -2,466 -3,131 -14,615 -7,817 14,355 -16,069 -11,985 -12,475
Net Cash From Continuing Investing Activities
-3,449 -2,266 -2,466 -3,131 -14,615 -7,817 14,355 -16,069 -11,985 -12,475
Purchase of Property, Plant & Equipment
-523 -585 -728 -579 -650 -825 -924 -590 -748 -747
Acquisitions
-4,840 -1,152 -1,797 -1,584 -25,920 -4,251 0.00 -10,426 0.00 0.00
Purchase of Investments
-736 -2,372 -1,942 -3,897 -20,770 -32,228 -10,389 -23,314 -25,976 -17,239
Sale and/or Maturity of Investments
2,592 1,844 2,002 2,910 32,718 29,921 25,858 18,261 14,739 5,511
Other Investing Activities, net
58 -1.00 -1.00 19 7.00 -434 -190 0.00 - -
Net Cash From Financing Activities
-3,433 -5,125 -6,469 -8,877 770 -7,634 -12,318 3,393 -9,725 -5,884
Net Cash From Continuing Financing Activities
-3,433 -5,126 -6,469 -8,877 770 -7,634 -12,318 3,393 -9,725 -5,884
Repayment of Debt
-2,251 -2,529 -1,673 -4,895 -2,638 -2,872 -6,736 -2,141 -2,257 -5,013
Repurchase of Common Equity
-1,150 -1,000 -1,396 -546 -1,583 -1,749 -2,900 -954 -11,001 -10,002
Payment of Dividends
-3,918 -3,809 -3,709 -3,605 -3,449 -3,222 -2,971 -2,731 -2,455 -1,874
Issuance of Debt
3,464 1,980 0.00 0.00 8,184 - 0.00 8,985 5,293 9,902
Issuance of Common Equity
422 232 309 169 256 209 289 234 208 319
Effect of Exchange Rate Changes
-40 57 -63 -35 43 -2.00 - - 41 -67
Cash Interest Paid
951 891 907 979 951 982 1,070 1,038 885 529
Cash Income Taxes Paid
2,779 3,990 3,136 2,509 2,639 1,793 3,198 3,342 2,436 3,137

Quarterly Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-2,065 4,955 2,264 -1,946 -1,367 380 1.00 768 -476 713 -40
Net Cash From Operating Activities
1,757 2,975 4,309 1,325 2,219 2,169 1,755 2,338 1,744 2,567 2,863
Net Cash From Continuing Operating Activities
1,758 2,976 4,309 1,324 2,219 2,167 1,756 2,337 1,745 2,567 2,863
Net Income / (Loss) Continuing Operations
1,315 1,783 1,253 1,614 -4,170 1,417 2,172 1,039 985 1,633 1,786
Consolidated Net Income / (Loss)
1,315 1,783 1,253 1,614 -4,170 1,417 2,172 1,039 985 1,633 1,786
Depreciation Expense
97 95 94 98 94 91 86 83 94 83 80
Amortization Expense
599 598 596 596 596 597 598 598 546 445 445
Non-Cash Adjustments To Reconcile Net Income
979 396 2,300 728 6,881 975 517 507 965 627 939
Changes in Operating Assets and Liabilities, net
-1,232 104 66 -1,712 -1,182 -913 -1,617 110 -845 -221 -387
Net Cash From Investing Activities
-415 -225 -710 -307 -2,207 -727 -229 -483 -826 -375 -713
Net Cash From Continuing Investing Activities
-416 -226 -709 -309 -2,205 -728 -229 -483 -826 -375 -713
Purchase of Property, Plant & Equipment
-104 -147 -141 -130 -105 -215 -122 -139 -109 -181 -157
Acquisitions
-273 -75 -570 -152 -4,043 -279 -79 -243 -551 -218 -448
Purchase of Investments
-16 -39 -9.00 -34 -654 -680 -395 -645 -652 -378 -430
Sale and/or Maturity of Investments
0.00 - - - 2,592 447 361 545 491 400 324
Other Investing Activities, net
-23 35 11 7.00 5.00 -1.00 6.00 -1.00 -5.00 2.00 -2.00
Net Cash From Financing Activities
-3,426 2,260 -1,379 -2,953 -1,361 -1,099 -1,519 -1,101 -1,406 -1,554 -2,118
Net Cash From Continuing Financing Activities
-3,426 2,260 -1,379 -2,954 -1,360 -1,100 -1,519 -1,100 -1,407 -1,554 -2,118
Repayment of Debt
-1,938 -54 -194 -1,887 -116 -34 -2,328 -32 -135 -23 -1,045
Repurchase of Common Equity
-730 -350 -300 -100 -400 -150 -300 -150 -400 -792 -180
Payment of Dividends
-1,010 -973 -983 -972 -990 -943 -953 -944 -969 -915 -929
Issuance of Common Equity
252 173 98 5.00 146 26 83 26 97 176 36
Effect of Exchange Rate Changes
19 -55 44 -11 -18 37 -6.00 13 13 75 -72

Annual Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
58,995 62,125 63,171 67,952 68,407 61,627 63,675 70,283 56,977 51,716
Total Current Assets
19,173 16,085 14,443 14,772 15,996 30,296 35,836 31,823 19,588 24,762
Cash & Equivalents
9,991 6,085 5,412 5,338 5,997 11,631 17,940 7,588 8,229 12,851
Short-Term Investments
0.00 1,179 973 1,182 1,411 12,721 12,149 17,922 3,666 1,756
Accounts Receivable
4,420 4,660 4,777 4,493 4,892 3,582 3,327 3,851 4,514 5,854
Inventories, net
1,710 1,787 1,507 1,618 1,683 922 814 801 1,587 1,955
Prepaid Expenses
3,052 2,374 1,774 2,141 2,013 1,440 1,606 1,661 1,592 1,518
Plant, Property, & Equipment, net
5,414 5,317 5,475 5,121 4,967 4,502 4,006 3,295 2,865 2,276
Total Noncurrent Assets
34,408 40,723 43,253 48,059 47,444 26,829 23,833 35,165 34,524 24,678
Long-Term Investments
0.00 1,163 1,245 1,309 502 1,488 1,423 11,184 20,485 11,601
Goodwill
8,314 8,314 8,314 8,332 8,108 4,117 4,117 4,159 1,172 1,172
Intangible Assets
19,948 26,454 28,894 33,455 33,126 13,786 15,738 17,100 8,971 10,247
Other Noncurrent Operating Assets
6,146 4,792 4,800 4,963 5,708 7,438 2,555 2,722 3,896 1,334
Total Liabilities & Shareholders' Equity
58,995 62,125 63,171 67,952 68,407 61,627 63,675 70,283 56,977 51,716
Total Liabilities
39,749 39,376 41,962 46,888 50,186 38,977 42,141 49,782 37,614 32,601
Total Current Liabilities
12,004 11,280 11,237 11,610 11,397 9,759 10,605 11,635 9,218 9,890
Short-Term Debt
1,815 1,798 2,273 1,516 2,757 2,499 2,748 2,747 0.00 982
Accounts Payable
833 550 905 705 5,180 713 790 814 1,206 1,178
Accrued Expenses
3,892 3,802 3,479 3,244 3,460 6,547 7,067 8,074 8,012 7,290
Other Current Liabilities
5,464 5,130 4,580 6,145 - - - - - -
Total Noncurrent Liabilities
27,745 28,096 30,725 35,278 38,789 29,218 31,536 38,147 28,396 22,711
Long-Term Debt
24,896 23,189 22,957 25,179 28,645 22,094 24,574 30,795 26,346 21,073
Noncurrent Deferred Revenue
830 2,039 3,916 4,767 5,016 6,115 5,922 6,794 1,753 1,243
Noncurrent Deferred & Payable Income Tax Liabilities
724 1,588 2,673 4,356 3,914 - - - - -
Other Noncurrent Operating Liabilities
1,295 1,280 1,179 976 1,214 1,009 1,040 558 297 395
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
19,246 22,749 21,209 21,064 18,221 22,650 21,534 20,501 19,363 19,113
Total Preferred & Common Equity
19,330 22,833 21,240 21,069 18,202 22,525 21,387 20,442 18,887 18,534
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
19,330 22,833 21,240 21,069 18,202 22,525 21,387 20,442 18,887 18,534
Common Stock
7,701 6,501 5,551 4,662 3,881 3,052 2,283 1,265 455 445
Retained Earnings
11,497 16,304 15,687 16,324 14,381 19,388 19,024 19,012 18,154 18,001
Accumulated Other Comprehensive Income / (Loss)
132 28 2.00 83 -60 85 80 165 278 88
Noncontrolling Interest
-84 -84 -31 -5.00 19 125 147 59 476 579

Quarterly Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
56,434 58,995 54,525 53,579 56,292 62,125 62,373 62,337 61,876 63,171 62,557
Total Current Assets
16,901 19,173 14,779 12,317 14,041 16,085 15,980 14,287 13,456 14,443 13,554
Cash & Equivalents
7,926 9,991 5,037 2,772 4,718 6,085 5,705 5,704 4,936 5,412 4,699
Accounts Receivable
4,388 4,420 4,587 4,663 4,669 4,660 4,790 4,229 4,162 4,777 4,354
Inventories, net
1,759 1,710 1,869 2,026 1,853 1,787 1,663 1,633 1,576 1,507 1,463
Prepaid Expenses
2,828 3,052 3,287 2,856 2,800 2,374 2,662 1,757 1,846 1,774 2,077
Plant, Property, & Equipment, net
5,421 5,414 5,391 5,346 5,321 5,317 5,572 5,540 5,479 5,475 5,349
Total Noncurrent Assets
34,112 34,408 34,354 35,916 36,930 40,723 40,822 42,511 42,941 43,253 43,654
Goodwill
8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314
Intangible Assets
19,355 19,948 20,546 22,832 23,428 26,454 27,152 27,750 28,348 28,894 29,440
Noncurrent Deferred & Refundable Income Taxes
2,572 - - - - - - - - - -
Other Noncurrent Operating Assets
3,871 6,146 5,494 4,770 5,188 4,792 4,200 5,113 4,952 4,800 4,618
Total Liabilities & Shareholders' Equity
56,434 58,995 54,525 53,579 56,292 62,125 62,373 62,337 61,876 63,171 62,557
Total Liabilities
37,355 39,749 36,134 35,384 38,837 39,376 40,130 41,243 40,937 41,962 41,500
Total Current Liabilities
12,344 12,004 11,725 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423
Short-Term Debt
2,806 1,815 1,812 1,810 3,667 1,798 1,793 4,037 2,283 2,273 2,270
Accounts Payable
737 833 903 537 622 550 586 622 627 905 614
Accrued Expenses
4,185 3,892 4,113 3,923 4,263 3,802 3,714 3,494 3,477 3,479 7,539
Other Current Liabilities
4,615 5,464 4,896 4,510 4,464 5,130 5,852 5,810 4,140 4,580 -
Total Noncurrent Liabilities
25,011 27,745 24,409 24,603 25,822 28,096 28,185 27,279 30,409 30,725 31,077
Long-Term Debt
22,146 24,896 21,437 21,540 21,527 23,189 23,189 21,209 22,956 22,957 22,953
Noncurrent Deferred Revenue
819 830 782 738 1,967 2,039 2,088 2,610 3,775 3,916 3,982
Noncurrent Deferred & Payable Income Tax Liabilities
709 724 794 907 933 1,588 1,984 2,106 2,401 2,673 3,036
Other Noncurrent Operating Liabilities
1,337 1,295 1,396 1,418 1,395 1,280 924 1,354 1,277 1,179 1,106
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
19,078 19,246 18,390 18,197 17,455 22,749 22,242 21,094 20,939 21,209 21,057
Total Preferred & Common Equity
19,162 19,330 18,475 18,281 17,539 22,833 22,314 21,158 20,997 21,240 21,081
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
19,162 19,330 18,474 18,281 17,539 22,833 22,313 21,157 20,997 21,240 21,081
Common Stock
8,139 7,701 7,328 7,023 6,814 6,501 6,280 6,009 5,794 5,551 5,227
Retained Earnings
10,931 11,497 11,073 11,165 10,656 16,304 16,002 15,138 15,223 15,687 15,756
Accumulated Other Comprehensive Income / (Loss)
92 132 73 93 69 28 31 10 -20 2.00 98
Noncontrolling Interest
-84 -84 -84 -84 -84 -84 -72 -64 -58 -31 -24

Annual Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
6.04% -0.60% -0.09% 10.60% 9.98% 1.46% -15.25% -14.09% -6.89% 31.13%
EBITDA Growth
-57.75% 18.57% -21.86% 174.11% -45.32% -26.65% -35.32% -17.10% -18.03% 43.68%
EBIT Growth
-78.62% 15.62% -27.27% 249.76% -56.90% -30.66% -39.40% -18.90% -19.18% 46.36%
NOPAT Growth
-81.46% 8.09% -22.52% 3,322.36% -95.13% -22.37% 18.41% -65.15% -25.02% 49.72%
Net Income Growth
-91.45% 22.93% -26.37% 6,867.42% -98.34% -1.76% 17.57% -65.57% -25.51% 50.15%
EPS Growth
-91.56% 23.63% -26.17% 4,830.00% -97.63% 1.20% 18.80% -64.69% -16.54% 62.04%
Operating Cash Flow Growth
35.25% -11.75% -20.31% 39.37% -10.67% 8.86% -29.40% -30.20% -19.78% 65.78%
Free Cash Flow Firm Growth
-21.42% -16.80% -25.35% 145.85% -5,155.00% -93.08% 593.73% -94.67% -22.68% 71.04%
Invested Capital Growth
-8.50% 1.29% -2.81% -4.27% 94.89% 23.40% -0.03% 30.16% -10.91% -9.39%
Revenue Q/Q Growth
1.61% -1.00% 0.53% -0.64% 6.66% 0.38% -0.69% -4.99% -3.76% 3.79%
EBITDA Q/Q Growth
13.20% -1.81% 16.49% -7.93% 0.34% 12.89% -10.34% -9.42% -7.10% 5.92%
EBIT Q/Q Growth
44.29% -4.33% 22.96% -10.46% -2.32% 16.48% -11.47% -10.74% -7.58% 6.21%
NOPAT Q/Q Growth
116.70% -6.46% 31.63% -19.08% -87.71% 63.99% 237.55% -59.59% -10.57% 7.52%
Net Income Q/Q Growth
321.05% -3.71% 37.99% -15.85% -92.79% 100.30% 236.83% -59.89% -10.52% 7.24%
EPS Q/Q Growth
322.22% -3.23% 37.36% -16.16% -89.80% 100.95% 239.02% -60.02% -7.71% 3.03%
Operating Cash Flow Q/Q Growth
8.04% -4.74% -6.57% 12.77% -7.52% 2.64% -4.63% -6.20% -11.69% 15.01%
Free Cash Flow Firm Q/Q Growth
43.51% -15.66% -6.50% 174.14% -1,614.20% -79.35% 224.28% -92.90% -12.65% 12.90%
Invested Capital Q/Q Growth
-1.74% 0.27% -1.34% -5.65% 101.40% 5.57% -10.97% 31.87% 3.97% -0.64%
Profitability Metrics
- - - - - - - - - -
Gross Margin
78.26% 76.04% 79.26% 75.82% 81.48% 79.18% 78.07% 83.26% 85.98% 87.73%
EBITDA Margin
15.42% 38.71% 32.45% 41.49% 16.74% 33.67% 46.57% 61.03% 63.24% 71.83%
Operating Margin
5.78% 28.05% 26.87% 36.32% 16.49% 19.10% 37.06% 54.10% 58.02% 68.00%
EBIT Margin
5.80% 28.78% 24.74% 33.98% 10.75% 27.42% 40.11% 56.10% 59.43% 68.47%
Profit (Net Income) Margin
1.67% 20.70% 16.74% 22.71% 0.36% 23.89% 24.68% 17.79% 44.38% 55.47%
Tax Burden Percent
69.57% 81.83% 78.53% 74.91% 5.33% 103.95% 70.01% 34.33% 78.89% 83.60%
Interest Burden Percent
41.37% 87.90% 86.15% 89.21% 62.91% 83.83% 87.87% 92.37% 94.66% 96.92%
Effective Tax Rate
30.58% 18.18% 21.47% 25.09% 94.67% -3.95% 29.99% 65.67% 21.11% 16.40%
Return on Invested Capital (ROIC)
3.07% 15.93% 14.62% 18.20% 0.69% 23.00% 33.09% 31.61% 98.34% 117.89%
ROIC Less NNEP Spread (ROIC-NNEP)
-0.98% 12.36% 8.09% 12.40% -0.46% -10.38% 40.74% 36.05% 106.64% 143.58%
Return on Net Nonoperating Assets (RNNOA)
-0.78% 9.61% 6.98% 13.37% -0.25% 1.28% -7.12% -8.31% -28.23% -14.28%
Return on Equity (ROE)
2.29% 25.54% 21.60% 31.57% 0.44% 24.28% 25.98% 23.30% 70.11% 103.61%
Cash Return on Invested Capital (CROIC)
11.95% 14.65% 17.47% 22.57% -63.67% 2.05% 33.12% 5.40% 109.89% 127.74%
Operating Return on Assets (OROA)
2.75% 12.46% 10.29% 13.61% 4.08% 9.82% 13.25% 23.02% 33.23% 51.74%
Return on Assets (ROA)
0.79% 8.96% 6.96% 9.10% 0.14% 8.56% 8.15% 7.30% 24.82% 41.92%
Return on Common Equity (ROCE)
2.30% 25.60% 21.62% 31.56% 0.43% 24.13% 25.85% 22.99% 68.18% 100.68%
Return on Equity Simple (ROE_SIMPLE)
2.48% 24.58% 21.50% 29.43% 0.49% 23.81% 25.53% 22.72% 71.41% 97.69%
Net Operating Profit after Tax (NOPAT)
1,154 6,222 5,757 7,430 217 4,456 5,741 4,848 13,911 18,552
NOPAT Margin
4.01% 22.95% 21.10% 27.21% 0.88% 19.85% 25.94% 18.57% 45.77% 56.84%
Net Nonoperating Expense Percent (NNEP)
4.05% 3.57% 6.53% 5.80% 1.15% 33.38% -7.65% -4.45% -8.30% -25.69%
Return On Investment Capital (ROIC_SIMPLE)
2.51% 13.04% 12.40% - - - - - - -
Cost of Revenue to Revenue
21.74% 23.96% 20.74% 24.18% 18.52% 20.83% 21.93% 16.74% 14.02% 12.27%
SG&A Expenses to Revenue
21.18% 22.46% 20.79% 19.21% 20.86% 19.52% 18.33% 14.85% 11.18% 10.50%
R&D to Revenue
36.76% 25.35% 21.70% 20.29% 44.13% 40.56% 22.68% 14.30% 16.78% 9.23%
Operating Expenses to Revenue
72.48% 47.99% 52.40% 39.50% 64.99% 60.08% 41.01% 29.16% 27.96% 19.73%
Earnings before Interest and Taxes (EBIT)
1,668 7,803 6,749 9,279 2,653 6,155 8,876 14,647 18,061 22,347
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4,435 10,496 8,852 11,329 4,133 7,559 10,305 15,933 19,219 23,445
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
5.96 4.25 4.69 3.89 3.46 3.03 3.02 3.55 3.76 5.79
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 14.76 42.21 0.00 8.12 15.08
Price to Revenue (P/Rev)
4.00 3.58 3.65 3.00 2.55 3.04 2.92 2.78 2.34 3.29
Price to Earnings (P/E)
239.83 17.12 21.69 13.17 512.71 12.67 11.85 15.66 5.26 5.92
Dividend Yield
3.33% 3.85% 3.68% 4.34% 5.41% 4.67% 4.56% 3.75% 3.41% 1.73%
Earnings Yield
0.42% 5.84% 4.61% 7.59% 0.20% 7.90% 8.44% 6.39% 19.01% 16.88%
Enterprise Value to Invested Capital (EV/IC)
3.66 2.89 3.02 2.53 2.08 3.13 3.49 4.00 4.91 6.93
Enterprise Value to Revenue (EV/Rev)
4.58 4.18 4.30 3.69 3.51 2.99 2.74 2.66 2.15 3.18
Enterprise Value to EBITDA (EV/EBITDA)
29.71 10.81 13.24 8.90 20.95 8.88 5.88 4.36 3.41 4.42
Enterprise Value to EBIT (EV/EBIT)
78.99 14.54 17.36 10.87 32.63 10.90 6.83 4.74 3.62 4.64
Enterprise Value to NOPAT (EV/NOPAT)
114.19 18.23 20.35 13.58 398.80 15.06 10.56 14.31 4.70 5.59
Enterprise Value to Operating Cash Flow (EV/OCF)
12.17 14.17 12.92 8.86 10.60 7.34 7.22 5.83 3.84 4.88
Enterprise Value to Free Cash Flow (EV/FCFF)
29.30 19.83 17.04 10.95 0.00 168.80 10.55 83.78 4.21 5.16
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
1.39 1.10 1.19 1.27 1.72 1.09 1.27 1.64 1.36 1.15
Long-Term Debt to Equity
1.29 1.02 1.08 1.20 1.57 0.98 1.14 1.50 1.36 1.10
Financial Leverage
0.79 0.78 0.86 1.08 0.54 -0.12 -0.17 -0.23 -0.26 -0.10
Leverage Ratio
2.88 2.85 3.10 3.47 3.18 2.84 3.19 3.19 2.82 2.47
Compound Leverage Factor
1.19 2.51 2.67 3.10 2.00 2.38 2.80 2.95 2.67 2.40
Debt to Total Capital
58.12% 52.34% 54.33% 55.90% 63.28% 52.06% 55.92% 62.07% 57.64% 53.57%
Short-Term Debt to Total Capital
3.95% 3.77% 4.89% 3.17% 5.56% 5.29% 5.62% 5.08% 0.00% 2.39%
Long-Term Debt to Total Capital
54.17% 48.58% 49.43% 52.72% 57.73% 46.77% 50.30% 56.98% 57.64% 51.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.18% -0.18% -0.07% -0.01% 0.04% 0.26% 0.30% 0.11% 1.04% 1.41%
Common Equity to Total Capital
42.06% 47.83% 45.74% 44.12% 36.68% 47.68% 43.78% 37.83% 41.32% 45.02%
Debt to EBITDA
6.02 2.38 2.85 2.36 7.60 3.25 2.65 2.11 1.37 0.94
Net Debt to EBITDA
3.77 1.58 1.99 1.67 5.68 -0.17 -0.41 -0.20 -0.31 -0.18
Long-Term Debt to EBITDA
5.61 2.21 2.59 2.22 6.93 2.92 2.38 1.93 1.37 0.90
Debt to NOPAT
23.15 4.02 4.38 3.59 144.65 5.52 4.76 6.92 1.89 1.19
Net Debt to NOPAT
14.49 2.66 3.06 2.54 108.21 -0.28 -0.73 -0.65 -0.43 -0.22
Long-Term Debt to NOPAT
21.58 3.73 3.99 3.39 131.95 4.96 4.28 6.35 1.89 1.14
Altman Z-Score
2.74 2.79 2.62 2.29 1.62 2.58 2.62 2.66 3.38 4.86
Noncontrolling Interest Sharing Ratio
-0.40% -0.26% -0.09% 0.04% 0.35% 0.62% 0.49% 1.34% 2.75% 2.83%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.60 1.43 1.29 1.27 1.40 3.10 3.38 2.74 2.13 2.50
Quick Ratio
1.20 1.06 0.99 0.95 1.08 2.86 3.15 2.52 1.78 2.07
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4,497 5,722 6,878 9,213 -20,093 397 5,746 828 15,544 20,102
Operating Cash Flow to CapEx
2,070.36% 1,368.55% 1,246.15% 1,966.15% 1,256.62% 1,108.36% 909.09% 2,016.61% 2,279.01% 2,844.71%
Free Cash Flow to Firm to Interest Expense
4.60 6.06 7.36 9.20 -20.42 0.40 5.33 0.74 16.12 29.22
Operating Cash Flow to Interest Expense
11.08 8.48 9.70 11.37 8.30 9.19 7.80 10.64 17.68 30.89
Operating Cash Flow Less CapEx to Interest Expense
10.55 7.86 8.92 10.79 7.64 8.36 6.94 10.11 16.91 29.80
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.47 0.43 0.42 0.40 0.38 0.36 0.33 0.41 0.56 0.76
Accounts Receivable Turnover
6.33 5.75 5.89 5.82 5.83 6.50 6.17 6.24 5.86 6.22
Inventory Turnover
3.58 3.95 3.62 4.00 3.51 5.39 6.01 3.66 2.41 2.40
Fixed Asset Turnover
5.36 5.03 5.15 5.41 5.21 5.28 6.06 8.48 11.82 16.53
Accounts Payable Turnover
9.04 8.93 7.03 2.24 1.55 6.22 6.05 4.33 3.57 3.76
Days Sales Outstanding (DSO)
57.63 63.51 62.01 62.73 62.64 56.17 59.20 58.48 62.26 58.65
Days Inventory Outstanding (DIO)
102.10 92.51 100.82 91.26 103.98 67.77 60.73 99.70 151.71 152.20
Days Payable Outstanding (DPO)
40.38 40.86 51.94 162.70 235.23 58.67 60.32 84.34 102.11 97.17
Cash Conversion Cycle (CCC)
119.35 115.16 110.89 -8.71 -68.61 65.26 59.62 73.84 111.86 113.68
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
35,966 39,309 38,809 39,930 41,713 21,403 17,344 17,349 13,329 14,962
Invested Capital Turnover
0.76 0.69 0.69 0.67 0.78 1.16 1.28 1.70 2.15 2.07
Increase / (Decrease) in Invested Capital
-3,343 500 -1,121 -1,783 20,310 4,059 -5.00 4,020 -1,633 -1,550
Enterprise Value (EV)
131,754 113,455 117,171 100,871 86,575 67,097 60,616 69,388 65,444 103,699
Market Capitalization
115,118 96,979 99,602 82,010 63,064 68,219 64,659 72,481 71,002 107,271
Book Value per Share
$15.51 $18.32 $16.93 $16.80 $14.52 $17.80 $16.53 $15.65 $14.34 $12.86
Tangible Book Value per Share
($7.17) ($9.58) ($12.73) ($16.52) ($18.37) $3.65 $1.18 ($0.63) $6.64 $4.94
Total Capital
45,957 47,736 46,439 47,759 49,623 47,243 48,856 54,043 45,709 41,170
Total Debt
26,711 24,987 25,230 26,695 31,402 24,593 27,322 33,542 26,346 22,055
Total Long-Term Debt
24,896 23,189 22,957 25,179 28,645 22,094 24,574 30,795 26,346 21,073
Net Debt
16,720 16,560 17,600 18,866 23,492 -1,247 -4,190 -3,152 -6,034 -4,153
Capital Expenditures (CapEx)
523 585 728 579 650 825 924 590 748 747
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1,007 -661 -906 -1,842 -52 -1,316 -2,110 -2,575 -1,525 1,247
Debt-free Net Working Capital (DFNWC)
8,984 6,603 5,479 4,678 7,356 23,036 27,979 22,935 10,370 15,854
Net Working Capital (NWC)
7,169 4,805 3,206 3,162 4,599 20,537 25,231 20,188 10,370 14,872
Net Nonoperating Expense (NNE)
674 609 1,191 1,229 128 -908 281 204 423 446
Net Nonoperating Obligations (NNO)
16,720 16,560 17,600 18,866 23,492 -1,247 -4,190 -3,152 -6,034 -4,153
Total Depreciation and Amortization (D&A)
2,767 2,693 2,103 2,050 1,480 1,404 1,429 1,286 1,158 1,098
Debt-free, Cash-free Net Working Capital to Revenue
-3.50% -2.44% -3.32% -6.75% -0.21% -5.86% -9.54% -9.86% -5.02% 3.82%
Debt-free Net Working Capital to Revenue
31.24% 24.35% 20.08% 17.13% 29.79% 102.61% 126.45% 87.85% 34.12% 48.57%
Net Working Capital to Revenue
24.93% 17.72% 11.75% 11.58% 18.63% 91.48% 114.03% 77.33% 34.12% 45.57%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.38 $4.54 $3.66 $4.96 $0.10 $4.24 $4.20 $3.54 $10.08 $12.37
Adjusted Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.26B 1.26B 1.26B 1.27B 1.30B 1.31B 1.34B 1.46B
Adjusted Diluted Earnings per Share
$0.38 $4.50 $3.64 $4.93 $0.10 $4.22 $4.17 $3.51 $9.94 $11.91
Adjusted Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.26B 1.26B 1.28B 1.31B 1.32B 1.36B 1.52B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.26B 1.26B 1.28B 1.31B 1.31B 1.37B
Normalized Net Operating Profit after Tax (NOPAT)
4,056 6,263 7,877 7,430 2,850 3,001 5,741 9,887 13,911 18,552
Normalized NOPAT Margin
14.10% 23.10% 28.87% 27.21% 11.54% 13.37% 25.94% 37.87% 45.77% 56.84%
Pre Tax Income Margin
2.40% 25.30% 21.31% 30.32% 6.76% 22.99% 35.25% 51.82% 56.26% 66.36%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
1.71 8.27 7.22 9.27 2.70 6.19 8.24 13.10 18.74 32.48
NOPAT to Interest Expense
1.18 6.59 6.16 7.42 0.22 4.48 5.33 4.34 14.43 26.97
EBIT Less CapEx to Interest Expense
1.17 7.65 6.44 8.69 2.04 5.36 7.38 12.57 17.96 31.40
NOPAT Less CapEx to Interest Expense
0.65 5.97 5.38 6.84 -0.44 3.65 4.47 3.81 13.65 25.88
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
816.25% 67.86% 81.23% 58.14% 3,875.28% 60.07% 54.41% 58.81% 18.20% 10.35%
Augmented Payout Ratio
1,055.83% 85.68% 111.80% 66.94% 5,653.93% 92.67% 107.53% 79.35% 99.76% 65.59%

Quarterly Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-0.28% 6.40% 7.01% 5.38% 5.26% -3.72% 0.13% 5.42% -3.61% 2.00% -5.11%
EBITDA Growth
173.57% 19.95% -41.76% 19.42% -263.10% -6.93% 1.54% 10.04% 255.32% 81.79% -24.34%
EBIT Growth
145.12% 26.89% -53.19% 25.98% -376.36% -15.64% -4.13% 4.13% 1,680.23% 126.38% -27.85%
NOPAT Growth
158.96% 45.92% -52.65% 90.93% -334.43% -24.19% 17.97% -28.90% 835.86% 291.43% -27.91%
Net Income Growth
131.53% 25.83% -42.31% 55.34% -523.35% -13.23% 21.61% -8.46% 8,108.33% 334.31% -30.94%
EPS Growth
131.14% 25.44% -42.20% 55.42% -517.50% -11.63% 21.83% -8.79% 3,900.00% 330.00% -30.73%
Operating Cash Flow Growth
-20.82% 37.16% 145.53% -43.33% 27.24% -15.50% -38.70% 29.74% -5.22% -19.91% -11.99%
Free Cash Flow Firm Growth
282.68% 507.74% 45.32% -24.51% -217.42% -70.04% -48.85% -52.86% -53.95% 30.91% 127.06%
Invested Capital Growth
-4.81% -8.50% -6.63% 1.13% -2.70% 1.29% -0.34% -2.77% -0.99% -2.81% -7.05%
Revenue Q/Q Growth
-11.92% 0.32% 8.50% 4.01% -6.02% 0.89% 6.85% 3.89% -14.03% 4.93% 12.49%
EBITDA Q/Q Growth
-16.21% 65.02% -36.84% 184.24% -236.61% -19.88% 29.50% 15.06% -22.05% -12.59% 40.35%
EBIT Q/Q Growth
-20.99% 102.35% -47.84% 154.10% -322.22% -25.36% 40.40% 18.68% -32.17% -15.18% 52.49%
NOPAT Q/Q Growth
-11.53% 73.25% -44.04% 168.75% -318.94% -43.78% 125.61% -15.59% -29.20% -12.51% 35.97%
Net Income Q/Q Growth
-26.25% 42.30% -22.37% 138.71% -394.28% -34.76% 109.05% 5.48% -39.68% -8.57% 57.36%
EPS Q/Q Growth
-27.27% 43.00% -22.48% 138.62% -392.98% -34.10% 108.43% 3.75% -37.98% -9.15% 56.04%
Operating Cash Flow Q/Q Growth
-40.94% -30.96% 225.21% -40.29% 2.31% 23.59% -24.94% 34.06% -32.06% -10.34% 58.88%
Free Cash Flow Firm Q/Q Growth
-32.70% 42.35% 128.74% 183.36% -323.89% -65.96% 18.82% 29.66% -42.88% -41.89% 9.52%
Invested Capital Q/Q Growth
0.39% -1.74% -5.60% 2.23% -3.51% 0.27% 2.26% -1.64% 0.44% -1.34% -0.24%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
76.90% 79.11% 79.14% 77.80% 76.79% 70.62% 77.80% 78.15% 77.94% 81.11% 80.19%
EBITDA Margin
39.07% 41.08% 24.97% 42.90% -52.96% 36.44% 45.88% 37.85% 34.18% 37.69% 45.24%
Operating Margin
33.55% 32.40% 11.77% 38.02% -64.64% 22.66% 37.20% 25.23% 26.84% 30.68% 40.29%
EBIT Margin
28.63% 31.92% 15.83% 32.92% -63.28% 26.76% 36.18% 27.53% 24.10% 30.55% 37.79%
Profit (Net Income) Margin
19.72% 23.56% 16.61% 23.21% -62.37% 19.92% 30.80% 15.74% 15.51% 22.10% 25.36%
Tax Burden Percent
79.75% 82.28% 131.07% 78.62% 92.96% 85.72% 93.70% 65.43% 75.77% 80.40% 73.44%
Interest Burden Percent
86.38% 89.69% 80.07% 89.69% 106.03% 86.82% 90.87% 87.40% 84.91% 89.99% 91.39%
Effective Tax Rate
20.25% 17.77% -31.07% 21.33% 0.00% 14.28% 6.30% 34.57% 24.31% 19.60% 26.56%
Return on Invested Capital (ROIC)
20.77% 20.35% 11.52% 21.57% -32.30% 13.49% 24.31% 11.62% 14.03% 17.09% 19.66%
ROIC Less NNEP Spread (ROIC-NNEP)
18.27% 18.95% 12.02% 19.11% -38.24% 13.69% 22.69% 11.35% 12.40% 16.05% 18.14%
Return on Net Nonoperating Assets (RNNOA)
18.75% 15.02% 10.41% 18.39% -38.36% 10.64% 18.47% 10.02% 11.38% 13.85% 16.69%
Return on Equity (ROE)
39.52% 35.37% 21.93% 39.96% -70.67% 24.12% 42.78% 21.64% 25.40% 30.94% 36.36%
Cash Return on Invested Capital (CROIC)
24.33% 11.95% 8.27% 3.33% 4.48% 14.65% 17.28% 18.94% 18.19% 17.47% 18.02%
Operating Return on Assets (OROA)
14.60% 15.16% 7.66% 15.79% -29.40% 11.58% 15.86% 12.04% 10.43% 12.71% 15.82%
Return on Assets (ROA)
10.06% 11.18% 8.04% 11.13% -28.98% 8.62% 13.51% 6.89% 6.71% 9.20% 10.62%
Return on Common Equity (ROCE)
39.71% 35.51% 22.01% 40.11% -70.93% 24.19% 42.88% 21.69% 25.45% 30.97% 36.38%
Return on Equity Simple (ROE_SIMPLE)
31.13% 0.00% 0.62% 5.65% 2.61% 0.00% 26.12% 25.73% 26.38% 0.00% 15.70%
Net Operating Profit after Tax (NOPAT)
1,784 2,016 1,164 2,080 -3,025 1,382 2,458 1,089 1,291 1,823 2,083
NOPAT Margin
26.76% 26.64% 15.43% 29.91% -45.25% 19.42% 34.86% 16.51% 20.32% 24.67% 29.59%
Net Nonoperating Expense Percent (NNEP)
2.50% 1.40% -0.51% 2.46% 5.94% -0.21% 1.62% 0.28% 1.63% 1.04% 1.52%
Return On Investment Capital (ROIC_SIMPLE)
4.05% 4.39% - - - 2.89% - - - 3.93% -
Cost of Revenue to Revenue
23.10% 20.89% 20.86% 22.20% 23.21% 29.38% 22.20% 21.85% 22.06% 18.89% 19.81%
SG&A Expenses to Revenue
18.87% 25.18% 18.99% 19.80% 20.57% 22.59% 18.65% 28.02% 20.77% 27.34% 17.23%
R&D to Revenue
24.48% 21.54% 25.18% 19.97% 84.52% 24.66% 21.95% 24.90% 30.35% 23.09% 22.68%
Operating Expenses to Revenue
43.35% 46.72% 67.37% 39.78% 141.43% 47.95% 40.60% 52.92% 51.12% 50.43% 39.90%
Earnings before Interest and Taxes (EBIT)
1,909 2,416 1,194 2,289 -4,231 1,904 2,551 1,817 1,531 2,257 2,661
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,605 3,109 1,884 2,983 -3,541 2,592 3,235 2,498 2,171 2,785 3,186
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
7.28 5.96 5.65 4.68 5.14 4.25 4.02 4.36 4.68 4.69 3.42
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
4.86 4.00 3.69 3.07 3.28 3.58 3.27 3.37 3.64 3.65 2.66
Price to Earnings (P/E)
23.39 239.83 821.89 81.10 185.91 17.12 15.26 16.82 17.62 21.69 21.66
Dividend Yield
2.77% 3.33% 3.65% 4.43% 4.17% 3.85% 4.14% 4.00% 3.73% 3.68% 5.03%
Earnings Yield
4.27% 0.42% 0.12% 1.23% 0.54% 5.84% 6.55% 5.94% 5.68% 4.61% 4.62%
Enterprise Value to Invested Capital (EV/IC)
4.33 3.66 3.35 2.73 2.91 2.89 2.72 2.85 2.98 3.02 2.30
Enterprise Value to Revenue (EV/Rev)
5.45 4.58 4.33 3.81 4.03 4.18 3.89 4.00 4.30 4.30 3.33
Enterprise Value to EBITDA (EV/EBITDA)
14.79 29.71 31.27 20.11 23.11 10.81 9.97 10.29 11.17 13.24 11.90
Enterprise Value to EBIT (EV/EBIT)
20.04 78.99 105.98 42.17 54.17 14.54 13.06 13.24 14.20 17.36 16.48
Enterprise Value to NOPAT (EV/NOPAT)
21.78 114.19 230.09 61.70 164.50 18.23 16.02 17.44 17.27 20.35 20.68
Enterprise Value to Operating Cash Flow (EV/OCF)
15.10 12.17 12.22 14.19 13.04 14.17 12.68 11.50 12.96 12.92 9.32
Enterprise Value to Free Cash Flow (EV/FCFF)
17.37 29.30 39.10 82.57 64.16 19.83 15.70 14.86 16.32 17.04 12.30
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.31 1.39 1.26 1.28 1.44 1.10 1.12 1.20 1.21 1.19 1.20
Long-Term Debt to Equity
1.16 1.29 1.17 1.18 1.23 1.02 1.04 1.01 1.10 1.08 1.09
Financial Leverage
1.03 0.79 0.87 0.96 1.00 0.78 0.81 0.88 0.92 0.86 0.92
Leverage Ratio
3.09 2.88 2.88 2.95 3.08 2.85 2.89 3.03 3.06 3.10 3.05
Compound Leverage Factor
2.67 2.59 2.30 2.65 3.26 2.47 2.62 2.65 2.60 2.79 2.79
Debt to Total Capital
56.67% 58.12% 55.83% 56.20% 59.07% 52.34% 52.90% 54.48% 54.66% 54.33% 54.50%
Short-Term Debt to Total Capital
6.37% 3.95% 4.35% 4.36% 8.60% 3.77% 3.80% 8.71% 4.94% 4.89% 4.90%
Long-Term Debt to Total Capital
50.30% 54.17% 51.48% 51.84% 50.47% 48.58% 49.10% 45.77% 49.71% 49.43% 49.60%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.19% -0.18% -0.20% -0.20% -0.20% -0.18% -0.15% -0.14% -0.13% -0.07% -0.05%
Common Equity to Total Capital
43.52% 42.06% 44.37% 44.00% 41.12% 47.83% 47.25% 45.66% 45.47% 45.74% 45.55%
Debt to EBITDA
2.36 6.02 5.93 4.43 5.27 2.38 2.34 2.37 2.42 2.85 3.32
Net Debt to EBITDA
1.61 3.77 4.65 3.91 4.28 1.58 1.59 1.62 1.73 1.99 2.41
Long-Term Debt to EBITDA
2.09 5.61 5.47 4.09 4.50 2.21 2.17 1.99 2.20 2.59 3.02
Debt to NOPAT
3.47 23.15 43.67 13.60 37.49 4.02 3.76 4.02 3.75 4.38 5.77
Net Debt to NOPAT
2.37 14.49 34.21 11.98 30.47 2.66 2.55 2.75 2.68 3.06 4.18
Long-Term Debt to NOPAT
3.08 21.58 40.26 12.54 32.03 3.73 3.49 3.38 3.41 3.99 5.25
Altman Z-Score
3.23 2.78 2.68 2.44 1.92 2.48 2.35 2.22 2.36 2.38 2.03
Noncontrolling Interest Sharing Ratio
-0.46% -0.40% -0.38% -0.37% -0.37% -0.26% -0.22% -0.20% -0.17% -0.09% -0.05%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.37 1.60 1.26 1.14 1.08 1.43 1.34 1.02 1.28 1.29 1.30
Quick Ratio
1.00 1.20 0.82 0.69 0.72 1.06 0.98 0.78 0.95 0.99 0.96
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
3,607 5,359 3,765 1,646 -1,974 882 2,591 2,180 1,682 2,944 5,065
Operating Cash Flow to CapEx
1,689.42% 2,023.81% 3,056.03% 1,019.23% 2,113.33% 1,008.84% 1,438.52% 1,682.01% 1,600.00% 1,418.23% 1,823.57%
Free Cash Flow to Firm to Interest Expense
13.87 21.61 15.82 6.94 -7.77 3.50 11.17 9.48 7.31 13.03 22.12
Operating Cash Flow to Interest Expense
6.76 12.00 18.11 5.59 8.74 8.61 7.56 10.17 7.58 11.36 12.50
Operating Cash Flow Less CapEx to Interest Expense
6.36 11.40 17.51 5.04 8.32 7.75 7.04 9.56 7.11 10.56 11.82
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.51 0.47 0.48 0.48 0.46 0.43 0.44 0.44 0.43 0.42 0.42
Accounts Receivable Turnover
6.35 6.33 6.04 6.25 6.22 5.75 5.99 6.56 6.80 5.89 6.08
Inventory Turnover
3.45 3.58 3.83 3.69 3.88 3.95 3.71 3.60 3.68 3.62 4.39
Fixed Asset Turnover
5.35 5.36 5.16 5.11 5.08 5.03 5.02 5.05 5.04 5.15 5.23
Accounts Payable Turnover
9.18 9.04 9.08 11.65 10.65 8.93 9.67 9.49 9.31 7.03 11.49
Days Sales Outstanding (DSO)
57.52 57.63 60.47 58.36 58.71 63.51 60.92 55.63 53.64 62.01 59.99
Days Inventory Outstanding (DIO)
105.66 102.10 95.35 98.91 94.12 92.51 98.29 101.29 99.06 100.82 83.17
Days Payable Outstanding (DPO)
39.75 40.38 40.20 31.33 34.28 40.86 37.73 38.45 39.20 51.94 31.77
Cash Conversion Cycle (CCC)
123.43 119.35 115.63 125.95 118.55 115.16 121.49 118.47 113.51 110.89 111.39
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
36,106 35,966 36,604 38,774 37,929 39,309 39,205 38,340 38,980 38,809 39,338
Invested Capital Turnover
0.78 0.76 0.75 0.72 0.71 0.69 0.70 0.70 0.69 0.69 0.66
Increase / (Decrease) in Invested Capital
-1,823 -3,343 -2,601 434 -1,051 500 -133 -1,091 -391 -1,121 -2,982
Enterprise Value (EV)
156,483 131,754 122,508 105,972 110,559 113,455 106,538 109,435 116,329 117,171 90,455
Market Capitalization
139,541 115,118 104,380 85,478 90,167 96,979 89,648 92,254 98,347 99,602 72,198
Book Value per Share
$15.39 $15.51 $14.84 $14.67 $14.07 $18.32 $17.91 $16.96 $16.84 $16.93 $16.82
Tangible Book Value per Share
($6.83) ($7.17) ($8.34) ($10.33) ($11.39) ($9.58) ($10.56) ($11.95) ($12.56) ($12.73) ($13.30)
Total Capital
44,030 45,957 41,639 41,547 42,649 47,736 47,224 46,340 46,178 46,439 46,280
Total Debt
24,952 26,711 23,249 23,350 25,194 24,987 24,982 25,246 25,239 25,230 25,223
Total Long-Term Debt
22,146 24,896 21,437 21,540 21,527 23,189 23,189 21,209 22,956 22,957 22,953
Net Debt
17,026 16,720 18,212 20,578 20,476 16,560 16,962 17,245 18,040 17,600 18,281
Capital Expenditures (CapEx)
104 147 141 130 105 215 122 139 109 181 157
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-563 -1,007 -171 574 -25 -661 -1,036 -2,307 -661 -906 -259
Debt-free Net Working Capital (DFNWC)
7,363 8,984 4,866 3,346 4,693 6,603 5,828 4,360 5,211 5,479 5,401
Net Working Capital (NWC)
4,557 7,169 3,054 1,536 1,026 4,805 4,035 323 2,928 3,206 3,131
Net Nonoperating Expense (NNE)
469 233 -89 466 1,145 -35 286 50 306 190 297
Net Nonoperating Obligations (NNO)
17,028 16,720 18,214 20,577 20,474 16,560 16,963 17,246 18,041 17,600 18,281
Total Depreciation and Amortization (D&A)
696 693 690 694 690 688 684 681 640 528 525
Debt-free, Cash-free Net Working Capital to Revenue
-1.96% -3.50% -0.60% 2.06% -0.09% -2.44% -3.78% -8.43% -2.44% -3.32% -0.95%
Debt-free Net Working Capital to Revenue
25.62% 31.24% 17.20% 12.03% 17.10% 24.35% 21.28% 15.92% 19.27% 20.08% 19.90%
Net Working Capital to Revenue
15.86% 24.93% 10.79% 5.52% 3.74% 17.72% 14.73% 1.18% 10.83% 11.75% 11.54%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.06 $1.43 $1.00 $1.29 ($3.34) $1.14 $1.75 $0.84 $0.81 $1.30 $1.43
Adjusted Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.26B 1.26B
Adjusted Diluted Earnings per Share
$1.04 $1.43 $1.00 $1.29 ($3.34) $1.14 $1.73 $0.83 $0.80 $1.29 $1.42
Adjusted Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.24B 1.25B 1.25B 1.24B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B
Normalized Net Operating Profit after Tax (NOPAT)
1,784 2,016 1,847 2,080 -1,324 1,425 2,458 1,089 1,291 1,823 2,083
Normalized NOPAT Margin
26.76% 26.64% 24.47% 29.91% -19.81% 20.03% 34.86% 16.51% 20.32% 24.67% 29.59%
Pre Tax Income Margin
24.73% 28.63% 12.67% 29.52% -67.10% 23.24% 32.87% 24.06% 20.47% 27.49% 34.54%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
7.34 9.74 5.02 9.66 -16.66 7.56 11.00 7.90 6.66 9.99 11.62
NOPAT to Interest Expense
6.86 8.13 4.89 8.78 -11.91 5.48 10.59 4.74 5.61 8.07 9.10
EBIT Less CapEx to Interest Expense
6.94 9.15 4.42 9.11 -17.07 6.70 10.47 7.30 6.18 9.19 10.93
NOPAT Less CapEx to Interest Expense
6.46 7.54 4.30 8.23 -12.32 4.63 10.07 4.13 5.14 7.26 8.41
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
66.02% 816.25% 3,410.53% 373.48% 836.24% 67.86% 64.87% 69.02% 67.39% 81.23% 111.45%
Augmented Payout Ratio
90.83% 1,055.83% 4,243.86% 465.44% 1,054.59% 85.68% 93.03% 96.99% 93.46% 111.80% 131.19%

Frequently Asked Questions About Gilead Sciences' Financials

When does Gilead Sciences's financial year end?

According to the most recent income statement we have on file, Gilead Sciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Gilead Sciences' net income changed over the last 9 years?

Gilead Sciences' net income appears to be on a downward trend, with a most recent value of $480 million in 2024, falling from $18.11 billion in 2015. The previous period was $5.61 billion in 2023. Check out Gilead Sciences' forecast to explore projected trends and price targets.

What is Gilead Sciences's operating income?
Gilead Sciences's total operating income in 2024 was $1.66 billion, based on the following breakdown:
  • Total Gross Profit: $22.50 billion
  • Total Operating Expenses: $20.84 billion
How has Gilead Sciences revenue changed over the last 9 years?

Over the last 9 years, Gilead Sciences' total revenue changed from $32.64 billion in 2015 to $28.75 billion in 2024, a change of -11.9%.

How much debt does Gilead Sciences have?

Gilead Sciences' total liabilities were at $39.75 billion at the end of 2024, a 0.9% increase from 2023, and a 21.9% increase since 2015.

How much cash does Gilead Sciences have?

In the past 9 years, Gilead Sciences' cash and equivalents has ranged from $5.34 billion in 2021 to $17.94 billion in 2018, and is currently $9.99 billion as of their latest financial filing in 2024.

How has Gilead Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Gilead Sciences' book value per share changed from 12.86 in 2015 to 15.51 in 2024, a change of 20.6%.



This page (NASDAQ:GILD) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners